Andrew K. Ottens

Andrew K. Ottens

Auto-generated profile, based on publicly available information

Andrew K. Ottens

Department of Neuroscience and Anatomy, Virginia Commonwealth University School of Medicine, Richmond, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2016 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CMChristen L. Mumaw
Christen L. Mumaw
SLShannon Levesque
Shannon Levesque
CMConstance McGraw
Constance McGraw
SRSarah Robertson
Sarah Robertson
SLSelita Lucas
Selita Lucas
MBMichelle L. Block
Michelle L. Block
Air pollution is implicated in neurodegenerative disease risk and progression and in microglial activation, but the mechanisms are unknown. In this study, microglia remained activated 24 h after ozone (O3) exposure in rats, suggesting a persistent signal from lung to brain. Ex vivo analysis of serum from O3‐treated rats revealed an augmented microglial proinflammatory response and β‐amyloid 42 (Aβ42) neurotoxicity independent of traditional circulating cytokines, where macrophage‐1 antigen‐mediated microglia proinflammatory priming. Aged mice exhibited reduced pulmonary immune profiles and the most pronounced neuroinflammation and microglial activation in response to mixed vehicle emissions. Consistent with this premise, cluster of differentiation 36 (CD36) –/– mice exhibited impaired pulmonary immune responses concurrent with augmented neuroinflammation and microglial activation in response to O 3 . Further, aging glia were more sensitive to the proinflammatory effects of O 3 serum. Together, these findings outline the lung‐brain axis, where air pollutant exposures result in circulating, cytokine‐independent signals present in serum that elevate the brain proinflammatory milieu, which is linked to the pulmonary response and is further augmented with age.—Mumaw, C. L., Levesque, S., McGraw, C., Robertson, S., Lucas, S., Stafflinger, J. E., Campen, M. J., Hall, P., Norenberg, J. P., Anderson, T., Lund, A. K., McDonald, J. D., Ottens, A. K., Block, M. L. Microglial priming through the lung‐brain axis: the role of air pollution‐induced circulating factors. FASEB J. 30, 1880–1891 (2016). www.fasebj.org

1 October 2006 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
Firas KobeissyFiras Kobeissy
Firas Kobeissy
AOAndrew K. Ottens
Andrew K. Ottens
ZZZhiqun Zhang
Zhiqun Zhang
MLMing Cheng Liu
Ming Cheng Liu
NDNancy D. Denslow
Nancy D. Denslow
KWKevin Wang
Kevin Wang
Approximately two million traumatic brain injury (TBI) incidents occur annually in the United States, yet there are no specific therapeutic treatments. The absence of brain injury diagnostic endpoints was identified as a significant roadblock to TBI therapeutic development. To this end, our laboratory has studied mechanisms of cellular injury for biomarker discovery and possible therapeutic strategies. In this study, pooled naïve and injured cortical samples (48 h postinjury; rat controlled cortical impact model) were processed and analyzed using a differential neuroproteomics platform. Protein separation was performed using combined cation/anion exchange chromatography-PAGE. Differential proteins were then trypsinized and analyzed with reversed-phase LC-MSMS for protein identification and quantitative confirmation. The results included 59 differential protein components of which 21 decreased and 38 increased in abundance after TBI. Proteins with decreased abundance included collapsin response mediator protein 2 (CRMP-2), glyceraldehyde-3-phosphate dehydrogenase, microtubule-associated proteins MAP2A/2B, and hexokinase. Conversely C-reactive protein, transferrin, and breakdown products of CRMP-2, synaptotagmin, and αII-spectrin were found to be elevated after TBI. Differential changes in the above mentioned proteins were confirmed by quantitative immunoblotting. Results from this work provide insight into mechanisms of traumatic brain injury and yield putative biochemical markers to potentially facilitate patient management by monitoring the severity, progression, and treatment of injury.

1 November 2010 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
GMGeoffrey T. Manley
Geoffrey T. Manley
RDRamon Diaz-Arrastia
Ramon Diaz-Arrastia
MBMary Brophy
Mary Brophy
DEDoortje Engel
Doortje Engel
CGClay Goodman
Clay Goodman
RHRonald L. Hayes
Ronald L. Hayes

21 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MAMario J. Aragon
Mario J. Aragon
LTLauren Topper
Lauren Topper
CTChristina R. Tyler
Christina R. Tyler
BSBethany Sanchez
Bethany Sanchez
KZKatherine Zychowski
Katherine Zychowski
MCMatthew J. Campen
Matthew J. Campen
Significance: Inhaled particulates, such as multiwalled carbon nanotubes, can induce neuroinflammatory outcomes. The present study shows that acute neuroinflammation is dependent on the impairment of blood-brain barrier function. Pharmacologic restoration of blood-brain barrier integrity prevented the neuroinflammatory responses to pulmonary multiwalled carbon nanotube exposure. Circulating factors, including possibly thrombospondin-1, recapitulate inflammatory responses in cultured cerebrovascular endothelial cells, suggesting a mechanism for indirect systemic effects of inhaled nanoparticles.

1 March 2007 in Journal of Neurotrauma
Verified
Journal Article
Closed access
ZZZhiqun Zhang
Zhiqun Zhang
AOAndrew K Ottens
Andrew K Ottens
SSShankar Sadasivan
Shankar Sadasivan
Firas KobeissyFiras Kobeissy
Firas Kobeissy
TFTie Fang
Tie Fang
KWKevin Wang
Kevin Wang
Collapsin response mediator proteins (CRMPs) are important molecules in neurite outgrowth and axonal guidance. Within the CRMP family, CRMP-2 has been implicated in several neurological diseases (Alzheimer's, epilepsy, and ischemia). Here, we investigated the integrity of CRMPs (CRMP-1, -2, -4, -5) after in vitro neurotoxin treatment and in vivo traumatic brain injury (TBI). After maitotoxin (MTX) and NMDA treatment of primary cortical neurons, a dramatic decrease of intact CRMP-1, -2 and -4 proteins were observed, accompanied by the appearance of distinct 55-kDa and 58-kDa breakdown products (BDP) for CRMP-2 and -4, respectively. Inhibition of calpain activation prevented NMDA-induced CRMP-2 proteolysis and redistribution of CRMP-2 from the neurites to the cell body, while attenuating neurite damage and neuronal cell injury. Similarly, CRMP-1, -2, and -4 were also found degraded in rat cortex and hippocampus following controlled cortical impact (CCI), an in vivo model of TBI. The appearance of the 55-kDa CRMP-2 BDP was observed to increase, in a time-dependent manner, between 24 and 48 h in the ipsilateral cortex, and by 48 hours in the hippocampus. The observed 55-kDa CRMP-2 BDP following TBI was reproduced by in vitro incubation of naive brain lysate with activated calpain-2, but not activated caspase-3. Sequence analysis revealed several possible cleavage sites near the C-terminus of CRMP-2. Collectively, this study demonstrated that CRMP-1, -2, and -4 are degraded following both acute traumatic and neurotoxic injury. Furthermore, calpain-2 was identified as the possible proteolytic mediator of CRMP-2 following excitotoxic injury and TBI, which appears to correlate well with neuronal cell injury and neurite damage. It is possible that the calpain-mediated truncation of CRMPs following TBI may be an inhibiting factor for post-injury neurite regeneration.

1 August 2005 in Expert Review of Proteomics
Verified
Journal Article
Closed access
KWKevin Wang
Kevin Wang
AOAndrew K Ottens
Andrew K Ottens
MLMing Cheng Liu
Ming Cheng Liu
SLStephen B Lewis
Stephen B Lewis
CMColleen Meegan
Colleen Meegan
RHRonald L Hayes
Ronald L Hayes
Traumatic brain injury (TBI) is a major national health problem without a US Food and Drug Administration-approved therapy. This review summarizes the importance of discovering relevant TBI protein biomarkers and presents logical rationale that neuroproteomic technologies are uniquely suited for the discovery of otherwise unnoticed TBI biomarkers. It highlights that one must make careful decisions when choosing which paradigm (human vs. animal models) and which biologic samples to use for such proteomic studies. It further outlines some of the desirable attributes of an ideal TBI biomarker and discusses how biomarkers discovered proteomically are complementary to those identified by traditional approaches. Lastly, the most important sequela of any proteomically identified TBI biomarker is validation in preclinical or clinical samples.